4579.T Live-Signale | Maximieren Sie Profite mit Getagraph.com

Live Chart Being Loaded With Signals

Commentary (26 Apr 2024 @ 08:15):

Stats
Tagesvolumen	95 100.00
Durchschnittsvolumen	124 670
Marktkapitalisierung	12.87B
EPS	¥0 ( 2024-02-14 )
Nächstes Ertragsdatum	( ¥0 ) 2024-05-12
Last Dividend	¥0 ( N/A )
Next Dividend	¥0 ( N/A )
P/E	-39.69
ATR14	¥0.734 (0.12%)

Volumen Korrelation

Lang: -0.01 (neutral)

Kurz: -0.62 (weak negative)

Signal:(47.079) Neutral

RaQualia Pharma Inc. Korrelation

10 Am meisten positiv korreliert

10 Am meisten negativ korreliert

Wussten Sie das?

Korrelation ist ein statistisches Maß, das die Beziehung zwischen zwei Variablen beschreibt. Es reicht von -1 bis 1, wobei -1 eine perfekte negative Korrelation (wenn eine Variable zunimmt, nimmt die andere ab) anzeigt, 1 eine perfekte positive Korrelation (wenn eine Variable zunimmt, nimmt die andere zu) und 0 keine Korrelation anzeigt (es besteht kein Zusammenhang zwischen den Variablen).

Korrelation kann verwendet werden, um die Beziehung zwischen beliebigen zwei Variablen zu analysieren, nicht nur zwischen Aktien. Es wird häufig in Bereichen wie Finanzen, Wirtschaft, Psychologie und mehr verwendet.

RaQualia Pharma Inc. Korrelation - Währung/Rohstoff

-0.06
( neutral )

0.31
( neutral )

0.35
( neutral )

0.14
( neutral )

-0.14
( neutral )

-0.31
( neutral )

RaQualia Pharma Inc. Finanzdaten

Annual	2023
Umsatz:	¥1.90B
Bruttogewinn:	¥1.48B (77.88 %)
EPS:	¥-14.98

FY	2023
Umsatz:	¥1.90B
Bruttogewinn:	¥1.48B (77.88 %)
EPS:	¥-14.98

FY	2022
Umsatz:	¥2.92B
Bruttogewinn:	¥2.69B (92.06 %)
EPS:	¥34.50

FY	2021
Umsatz:	¥2.78B
Bruttogewinn:	¥2.46B (88.45 %)
EPS:	¥7.20

Financial Reports:

No articles found.

RaQualia Pharma Inc.

RaQualia Pharma Inc. engages in the research and development of pharmaceutical compounds worldwide. Its human products portfolio includes tegoprazan for gastroesophageal reflux disease, which is in phase 1 clinical trial in the United States; and grapiprant for pain management, which is in phase II clinical trial in the United States and phase I clinical trial in China, as well as in phase I clinical trial in China and the United States to treat cancer. The company also provides veterinary products such as, grapiprant for osteoarthritis in dogs; ghrelin receptor agonist to treat cancer-related anorexia/cachexia syndrome, and constipation resulting from spinal cord injury; and ELURA, a drug for the management of weight loss in cats with chronic kidney disease. In addition, it provides TRPM8 blocker for the target indication of neuropathic pain; motilin receptor agonist to treat gastrointestinal dysmotility, including gastroparesis, functional dyspepsia, and post-operative ileus; potassium-competitive acid blocker to treat gastro-esophageal reflux disease that has completed phase 1 clinical trial; 5-HT4 partial agonist to treat gastroparesis, functional dyspepsia, and chronic constipation; 5-HT2B antagonist to treat irritable bowel syndrome with diarrhea; EP4 antagonist, a pain management drugs for dogs; serotonin 5-HT2A and dopamine D2 receptor blocker to treat schizophrenia; EP4 antagonist to treat cancer that is in phase I clinical trial, as well as in phase 1 clinical trial for the indication of pain; Cyclooxygenase-2 inhibitor, Phase I clinical trials for the indication of pain; CB2 agonist; selective sodium channel blocker; P2X7 receptor antagonist, which is in Phase I clinical trials for the target indication of neuropathic pain; and retinoic acid receptor alpha agonist. It has a collaborative agreement with Interprotein Corporation, ASKA Pharmaceutical. Co., Ltd., and Epigeneron, Inc. The company was incorporated in 2008 and is headquartered in Nagoya, Japan.